AbbVie and Alvotech Settle Over Alleged Stolen Trade Secrets on Blockbuster Humira

March 10, 2022

AbbVie has settled with Alvotech over allegations that the Icelandic drugmaker tried to market a biosimilar version of AbbVie’s blockbuster rheumatoid arthritis medicine Humira (adalimumab) after allegedly stealing trade secrets about the drug through an AbbVie ex-employee.

The settlement stipulates that AbbVie will grant Alvotech a nonexclusive license to its Humira-related patents in the U.S. — but not until July 1, 2023.

Alvotech will pay royalties to AbbVie for licensing the patents “and acknowledges the validity and enforceability of the licensed patents,” according to the deal.

View today's stories